Switch theme
Sign up to access all valuation multiples
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
2016
202
LTM Revenue $43.3M
LTM EBITDA -$96.4M
-$118M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Metagenomi has a last 12-month revenue (LTM) of $43.3M and a last 12-month EBITDA of -$96.4M.
In the most recent fiscal year, Metagenomi achieved revenue of $52.3M and an EBITDA of -$83.5M.
Metagenomi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Metagenomi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $43.3M | XXX | $52.3M | XXX | XXX | XXX |
| Gross Profit | $43.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$96.4M | XXX | -$83.5M | XXX | XXX | XXX |
| EBITDA Margin | -223% | XXX | -160% | XXX | XXX | XXX |
| EBIT | -$94.5M | XXX | -$88.9M | XXX | XXX | XXX |
| EBIT Margin | -218% | XXX | -170% | XXX | XXX | XXX |
| Net Profit | -$86.1M | XXX | -$78.1M | XXX | XXX | XXX |
| Net Margin | -199% | XXX | -149% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Metagenomi's stock price is $2.
Metagenomi has current market cap of $63.5M, and EV of -$118M.
See Metagenomi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$118M | $63.5M | XXX | XXX | XXX | XXX | $-2.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Metagenomi has market cap of $63.5M and EV of -$118M.
Metagenomi's trades at -2.3x EV/Revenue multiple, and 1.4x EV/EBITDA.
Equity research analysts estimate Metagenomi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Metagenomi has a P/E ratio of -0.7x.
See valuation multiples for Metagenomi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $63.5M | XXX | $63.5M | XXX | XXX | XXX |
| EV (current) | -$118M | XXX | -$118M | XXX | XXX | XXX |
| EV/Revenue | -2.7x | XXX | -2.3x | XXX | XXX | XXX |
| EV/EBITDA | 1.2x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBIT | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/Gross Profit | -2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMetagenomi's last 12 month revenue growth is -25%
Metagenomi's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.
Metagenomi's rule of 40 is -150% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Metagenomi's rule of X is -284% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Metagenomi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -25% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -223% | XXX | -160% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 41% | XXX | XXX | XXX |
| Rule of 40 | -150% | XXX | -184% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -284% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 209% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 270% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Metagenomi acquired XXX companies to date.
Last acquisition by Metagenomi was XXXXXXXX, XXXXX XXXXX XXXXXX . Metagenomi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Metagenomi founded? | Metagenomi was founded in 2016. |
| Where is Metagenomi headquartered? | Metagenomi is headquartered in United States of America. |
| How many employees does Metagenomi have? | As of today, Metagenomi has 202 employees. |
| Who is the CEO of Metagenomi? | Metagenomi's CEO is Dr. Brian C. Thomas, PhD. |
| Is Metagenomi publicy listed? | Yes, Metagenomi is a public company listed on NAS. |
| What is the stock symbol of Metagenomi? | Metagenomi trades under MGX ticker. |
| When did Metagenomi go public? | Metagenomi went public in 2024. |
| Who are competitors of Metagenomi? | Similar companies to Metagenomi include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Metagenomi? | Metagenomi's current market cap is $63.5M |
| What is the current revenue of Metagenomi? | Metagenomi's last 12 months revenue is $43.3M. |
| What is the current revenue growth of Metagenomi? | Metagenomi revenue growth (NTM/LTM) is -25%. |
| What is the current EV/Revenue multiple of Metagenomi? | Current revenue multiple of Metagenomi is -2.7x. |
| Is Metagenomi profitable? | Yes, Metagenomi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Metagenomi? | Metagenomi's last 12 months EBITDA is -$96.4M. |
| What is Metagenomi's EBITDA margin? | Metagenomi's last 12 months EBITDA margin is -223%. |
| What is the current EV/EBITDA multiple of Metagenomi? | Current EBITDA multiple of Metagenomi is 1.2x. |
| What is the current FCF of Metagenomi? | Metagenomi's last 12 months FCF is -$113M. |
| What is Metagenomi's FCF margin? | Metagenomi's last 12 months FCF margin is -261%. |
| What is the current EV/FCF multiple of Metagenomi? | Current FCF multiple of Metagenomi is 1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
